Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.53 |
| ▸ | LPL | P06858 | 12/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429978 | 0.84 | LIPG (0.53) | LIPGLPLIRAK4EGFRIDO1 | |
| SCHEMBL2358141 | 0.84 | LIPG (0.53) | LIPGLPLIRAK4EGFRPRMT5 | |
| SCHEMBL23043783 | 0.84 | CYP2A6 (0.49) | LIPGLPLIRAK4 | |
| SCHEMBL30640509 | 0.84 | CYP2A6 (0.49) | LIPGLPLIRAK4 | |
| SCHEMBL29444278 | 0.83 | LPL (0.59) | LIPGLPLIRAK4EGFRPRMT5 | |
| SCHEMBL2453344 | 0.83 | LPL (0.59) | LIPGLPLIRAK4EGFRPRMT5 | |
| SCHEMBL30876507 | 0.83 | LPL (0.42) | LIPGLPLIRAK4IDO1TDO2 | |
| SCHEMBL28706226 | 0.83 | LIPG (0.51) | LIPGLPLIRAK4EGFRIDO1 | |
| SCHEMBL23043319 | 0.83 | LPL (0.42) | LIPGLPLIRAK4IDO1TDO2 | |
| SCHEMBL29341518 | 0.83 | LIPG (0.51) | LIPGLPLIRAK4EGFRPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098351-A1 | Lactone compounds which can be used as antioxidant agents in pharmaceutical, cosmetic or food compositions and their method of preparation | COMMISSISSARIAT A L'ENERGIE ATOMIQUE | 2011-04-28 | — | — | US | disclosed |
| US-20110098351-A1 | Lactone compounds which can be used as antioxidant agents in pharmaceutical, cosmetic or food compositions and their method of preparation | COMMISSISSARIAT A L'ENERGIE ATOMIQUE | 2011-04-28 | — | — | US | disclosed |
| US-20110098351-A1 | Lactone compounds which can be used as antioxidant agents in pharmaceutical, cosmetic or food compositions and their method of preparation | COMMISSISSARIAT A L'ENERGIE ATOMIQUE | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098351-A1 | Lactone compounds which can be used as antioxidant agents in pharmaceutical, cosmetic or food compositions and their method of preparation | NQO1, LPO, CAT | LIPG 159/4885LPL 84/4885IRAK4 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.